Cholesterol lowering in intermediate-risk persons without cardiovascular disease

Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear wheth...

Full description

Bibliographic Details
Main Authors:	Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Jun, Zhu, Xavier, Denis, Lisheng, Liu, Md Aris, Mohd Aznan, Mohd Shah, Azarisman Shah, ., et. al
Format:	Article
Language:	English English
Published:	Massachusetts Medical Society 2016
Subjects:	R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine
Online Access:	http://irep.iium.edu.my/50353/ http://irep.iium.edu.my/50353/ http://irep.iium.edu.my/50353/ http://irep.iium.edu.my/50353/7/Cholesterol_Lowering_in_Intermediate-Risk.pdf http://irep.iium.edu.my/50353/11/DR_AZNAN.pdf

id	iium-50353
recordtype	eprints
spelling	iium-503532017-10-19T12:26:05Z http://irep.iium.edu.my/50353/ Cholesterol lowering in intermediate-risk persons without cardiovascular disease Yusuf, Salim Bosch, Jackie Dagenais, Gilles Jun, Zhu Xavier, Denis Lisheng, Liu Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. Massachusetts Medical Society 2016-04-06 Article PeerReviewed application/pdf en http://irep.iium.edu.my/50353/7/Cholesterol_Lowering_in_Intermediate-Risk.pdf application/pdf en http://irep.iium.edu.my/50353/11/DR_AZNAN.pdf Yusuf, Salim and Bosch, Jackie and Dagenais, Gilles and Jun, Zhu and Xavier, Denis and Lisheng, Liu and Md Aris, Mohd Aznan and Mohd Shah, Azarisman Shah and ., et. al (2016) Cholesterol lowering in intermediate-risk persons without cardiovascular disease. New England Journal of Medicine, 374 (21). pp. 2021-2031. ISSN 0028-4793 E-ISSN 1533-4406 htpp://www.nejm.orl.com 10.1056/NEJMoa1600176
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English English
topic	R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine
spellingShingle	R Medicine (General) RC Internal medicine RJ Pediatrics RZ Other systems of medicine Yusuf, Salim Bosch, Jackie Dagenais, Gilles Jun, Zhu Xavier, Denis Lisheng, Liu Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al Cholesterol lowering in intermediate-risk persons without cardiovascular disease
description	Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years.
format	Article
author	Yusuf, Salim Bosch, Jackie Dagenais, Gilles Jun, Zhu Xavier, Denis Lisheng, Liu Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al
author_facet	Yusuf, Salim Bosch, Jackie Dagenais, Gilles Jun, Zhu Xavier, Denis Lisheng, Liu Md Aris, Mohd Aznan Mohd Shah, Azarisman Shah ., et. al
author_sort	Yusuf, Salim
title	Cholesterol lowering in intermediate-risk persons without cardiovascular disease
title_short	Cholesterol lowering in intermediate-risk persons without cardiovascular disease
title_full	Cholesterol lowering in intermediate-risk persons without cardiovascular disease
title_fullStr	Cholesterol lowering in intermediate-risk persons without cardiovascular disease
title_full_unstemmed	Cholesterol lowering in intermediate-risk persons without cardiovascular disease
title_sort	cholesterol lowering in intermediate-risk persons without cardiovascular disease
publisher	Massachusetts Medical Society
publishDate	2016
url	http://irep.iium.edu.my/50353/ http://irep.iium.edu.my/50353/ http://irep.iium.edu.my/50353/ http://irep.iium.edu.my/50353/7/Cholesterol_Lowering_in_Intermediate-Risk.pdf http://irep.iium.edu.my/50353/11/DR_AZNAN.pdf
first_indexed	2023-09-18T21:11:10Z
last_indexed	2023-09-18T21:11:10Z
_version_	1777411261820043264

Cholesterol lowering in intermediate-risk persons without cardiovascular disease

Similar Items